Department of Clinical Biochemistry, Copenhagen University Hospital-Herlev and Gentofte, Borgmester Ib Juuls Vej 73, Entrance 7, 4. Floor, M3, DK-2730 Herlev, Copenhagen, Denmark.
The Copenhagen General Population Study, Copenhagen University Hospital-Herlev and Gentofte, Borgmester Ib Juuls Vej 73, Entrance 7, 4. Floor, M3, DK-2730 Herlev, Copenhagen, Denmark.
Cardiovasc Res. 2024 Feb 27;120(1):95-107. doi: 10.1093/cvr/cvad162.
Adiponectin may play an important protective role in heart failure and associated cardiovascular diseases. We hypothesized that plasma adiponectin is associated observationally and causally, genetically with risk of heart failure, atrial fibrillation, aortic valve stenosis, and myocardial infarction.
In the Copenhagen General Population Study, we examined 30 045 individuals with plasma adiponectin measurements observationally and 96 903 individuals genetically in one-sample Mendelian randomization analyses using five genetic variants explaining 3% of the variation in plasma adiponectin. In the HERMES, UK Biobank, The Nord-Trøndelag Health Study (HUNT), deCODE, the Michigan Genomics Initiative (MGI), DiscovEHR, and the AFGen consortia, we performed two-sample Mendelian randomization analyses in up to 1 030 836 individuals using 12 genetic variants explaining 14% of the variation in plasma adiponectin.In observational analyses modelled linearly, a 1 unit log-transformed higher plasma adiponectin was associated with a hazard ratio of 1.51 (95% confidence interval: 1.37-1.66) for heart failure, 1.63 (1.50-1.78) for atrial fibrillation, 1.21 (1.03-1.41) for aortic valve stenosis, and 1.03 (0.93-1.14) for myocardial infarction; levels above the median were also associated with an increased risk of myocardial infarction, and non-linear U-shaped associations were more apparent for heart failure, aortic valve stenosis, and myocardial infarction in less-adjusted models. Corresponding genetic, causal risk ratios were 0.92 (0.65-1.29), 0.87 (0.68-1.12), 1.55 (0.87-2.76), and 0.93 (0.67-1.30) in one-sample Mendelian randomization analyses, and no significant associations were seen for non-linear one-sample Mendelian randomization analyses; corresponding causal risk ratios were 0.99 (0.89-1.09), 1.00 (0.92-1.08), 1.01 (0.79-1.28), and 0.99 (0.86-1.13) in two-sample Mendelian randomization analyses, respectively.
Observationally, elevated plasma adiponectin was associated with an increased risk of heart failure, atrial fibrillation, aortic valve stenosis, and myocardial infarction. However, genetic evidence did not support causality for these associations.
脂联素可能在心力衰竭和相关心血管疾病中发挥重要的保护作用。我们假设,血浆脂联素与心力衰竭、心房颤动、主动脉瓣狭窄和心肌梗死的风险具有观察性和因果关系,也与遗传有关。
在哥本哈根普通人群研究中,我们观察性地检测了 30045 名个体的血浆脂联素,在一项单样本孟德尔随机分析中使用 5 个解释血浆脂联素 3%变异的遗传变异体对 96903 名个体进行了遗传分析。在 HERMES、英国生物银行、特隆赫姆健康研究(HUNT)、deCODE、密歇根基因组倡议(MGI)、DiscovEHR 和 AFGen 联盟中,我们使用 12 个解释血浆脂联素 14%变异的遗传变异体,在多达 1030836 名个体中进行了两样本孟德尔随机分析。在线性模型中,观察到每增加一个单位的对数转换后的血浆脂联素水平,心力衰竭的风险比为 1.51(95%置信区间:1.37-1.66),心房颤动为 1.63(1.50-1.78),主动脉瓣狭窄为 1.21(1.03-1.41),心肌梗死为 1.03(0.93-1.14);中位数以上的水平也与心肌梗死风险增加有关,在未经调整的模型中,心力衰竭、主动脉瓣狭窄和心肌梗死的非线性 U 型关联更为明显。在单样本孟德尔随机分析中,相应的遗传因果风险比为 0.92(0.65-1.29)、0.87(0.68-1.12)、1.55(0.87-2.76)和 0.93(0.67-1.30),而非线性单样本孟德尔随机分析中未见显著关联;在两样本孟德尔随机分析中,相应的因果风险比分别为 0.99(0.89-1.09)、1.00(0.92-1.08)、1.01(0.79-1.28)和 0.99(0.86-1.13)。
观察性研究表明,血浆脂联素水平升高与心力衰竭、心房颤动、主动脉瓣狭窄和心肌梗死的风险增加有关。然而,遗传证据并不支持这些关联的因果关系。